Muehlmeier G, Biesinger E, Maier H
Department of ENT, Head and Neck Surgery, German Armed Forces Hospital Ulm, Ulm, Germany. gment @ t-online.de
Audiol Neurootol. 2011;16(6):388-97. doi: 10.1159/000322641. Epub 2011 Jan 21.
Effective pharmacological treatments for tinnitus have proven elusive. Emerging evidence suggests that dysregulation of cochlear N-methyl-D-aspartate (NMDA) receptors may underlie aberrant excitation of the auditory nerve, which in turn is perceived as tinnitus. The blocking of these receptors thus represents a promising therapeutic approach. In a recent phase I/II clinical trial, the safety and local tolerance of intratympanic injections of the NMDA receptor antagonist AM-101 was evaluated for the first time in humans. The results from the double-blind, randomized, placebo-controlled study show that intratympanically injected AM-101 was well tolerated by study participants, and provided the first indications of therapeutic efficacy.
事实证明，有效的耳鸣药物治疗方法难以捉摸。新出现的证据表明，耳蜗N-甲基-D-天冬氨酸（NMDA）受体失调可能是听神经异常兴奋的基础，而这种异常兴奋反过来又被感知为耳鸣。因此，阻断这些受体是一种很有前景的治疗方法。在最近的一项I/II期临床试验中，首次在人体中评估了鼓室内注射NMDA受体拮抗剂AM-101的安全性和局部耐受性。这项双盲、随机、安慰剂对照研究的结果表明，鼓室内注射AM-101的受试者耐受性良好，并首次显示出治疗效果。
